Cannabis Reduction and Functional Outcomes

NCT07218471 | Recruiting DMC

• 2 other identifiers: Pro00145652NIDA R01 DA062443
• Study Type: interventional
• Target: 176
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.

Conditions

Cannabis Use Disorder

Outcome Measures

Primary Outcomes (1)

• Cannabis-Related Problems

  Rutgers Marijuana Problem Index (RMPI)- higher scores associated with worse outcomes.

  Week 8 (end-of-treatment)

Secondary Outcomes (9)

• Total minutes of sleep per night

  Week 8 (end-of-treatment)

• Minutes of light sleep per night

  Week 8 (end-of-treatment)

• Minutes of rapid eye movement (REM) sleep per night

  Week 8 (end-of-treatment)

• Minutes of deep sleep per night

  Week 8 (end-of-treatment)

• Sleep efficiency rating

  Week 8 (end-of-treatment)

Other Outcomes (2)

• DSM-5 CUD Criteria and Severity

  Week 8 (end-of-treatment)

• Quality of Life Enjoyment and Satisfaction-Q-SF

  Week 8 (end-of-treatment)

Interventions

Motivational Interviewing BEHAVIORAL

Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.

CBT4CBT (Computerized Cognitive Behavioral Therapy) BEHAVIORAL

Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.

Contingency Management BEHAVIORAL

Patients will receive contingent reinforcers (financial incentives for reduction in urinary cannabinoids).

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18+
• Urinary cannabinoid level ≥ 50 ng/mL
• DSM-5 diagnosis of CUD (mild, moderate, or severe)
• Willingness to attempt cannabis reduction
• Completion of Intake Visit

You may not qualify if:

• Serious medical/psychiatric conditions
• Pregnancy or breastfeeding
• Use of cannabis in past 30 days was for medical purposes only
• Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition
• Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz

Sponsors & Collaborators

• Medical University of South Carolina: lead
• National Institutes of Health (NIH): collaborator
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

RECRUITING

MeSH Terms

Interventions

Motivational Interviewing

Intervention Hierarchy (Ancestors)

Directive Counseling; Counseling; Mental Health Services; Behavioral Disciplines and Activities; Health Services; Health Care Facilities Workforce and Services

Study Officials

• Rachel Tomko, PhD.

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

• Erin McClure, PhD.

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rachel Tomko, PhD

CONTACT

(843) 792-5447; tomko@musc.edu

Erin McClure, PhD

CONTACT

(843) 792-7192; mccluree@musc.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor-Faculty

Study Record Dates

• First Submitted: October 13, 2025
• First Posted: October 20, 2025
• Study Start: March 13, 2026
• Primary Completion (Estimated): September 15, 2029
• Study Completion (Estimated): January 30, 2030
• Last Updated: March 19, 2026

Record last verified: 2025-10

Locations

US (1)